Hilary Koprowski Endowed Professorship Established At The Wistar Institute

July 24, 1998

PHILADELPHIA, Penn. -- Giovanni Rovera, M.D., Director and CEO, and the Board of Managers announce the establishment of the Hilary Koprowski Endowed Professorship at The Wistar Institute. Funding for the chair, which is Wistar's first, was provided by The Wistar Science Trust Fund, created in 1990 by Dr. Koprowsi for the benefit of Wistar research, and The Wistar Institute.

"The Hilary Koprowski Endowed Professorship is designed to support an eminent scientist who brings luster to the Institute," explained Dr. Koprowski, Professor Laureate of The Wistar Institute and Wistar Professor of Research Medicine at the University of Pennsylvania.

The Hilary Koprowski Institute Professor may be a current member of Wistar's faculty or a new recruit. Selection of the first chair holder will be made by Dr. Rovera, Barry Cooperman, Ph.D., Co-Chair with Dr. Koprowski of Wistar's Scientific Advisory Committee, and Dr. Koprowski.

"The Hilary Koprowski Endowed Professorship will hopefully provide long-term support for distinguished scientists and set a precedent for the establishment of additional endowed professorships at Wistar," said Dr. Rovera. Roughly 50 percent of Wistar's support comes from the federal government, and 20 percent from charitable donations.

Dr. Koprowski, for whom the professorship is named, served as Wistar's Director from 1957 until 1991. Under his leadership, the Institute evolved into a world-renowned medical research facility. In 1997, Dr. Koprowski was awarded the Chevalier Légion d'Honneur for a career distinguished by outstanding scientific achievement.

The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and discovery of genes that contribute to the development of diseases like leukemia, lymphoma, and breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.
-end-


The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.